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Abstract The aminopeptidase N (CD13, EC 3.4.11.2) is a well- 
characterized surface molecule xpressed in a variety of cell types 
and species. Recent data indicate an expression of the APN 
mRNA and the corresponding aminopeptidase activity in human 
peripheral T cells and related cell lines as well. Here, the sensitive 
method of competitive PCR was used to quantify low amounts of 
APN mRNA in T cell lines. An APN cDNA fragment en- 
shortened by a deletion of 87 bp was used as an internal APN- 
specific standard. The myelo-monocytic cell line U937 and the 
lymphoid T cell lines HUT78 and H9 contain 2.3 x 107, 5.9 x 106 
and 5.6 x 106 copies/rig total RNA, corresponding to 160, 70 and 
50 copies/cell, respectively. These data have been confirmed by 
determination of the APN activity, that represents a fraction only 
of the total cellular neutral aminopeptidase activity in hematopo- 
etic cells. In the ease of the CD 13-positive cell line U937, ~ 60-70% 
of the total neutral aminopeptidase activity could be attributed 
to APN. In contrast, only a minor fraction (5-20%) of the cellular 
neutral aminopeptidase activity in the T cell lines H9 and HUT78 
represents APN. The results suggest hat APN gene expression 
within the hematopoetic system is not restricted to myelo-mon- 
ocytic cells, instead a low APN expression may be a common 
feature of lymphocytes, at least of T cells, too. 
the occurrence of neutral aminopeptidase activity on these cells 
[13-16,18]. These results suggest that the aminopeptidase N 
(CD 13) is expressed in lymphoid cells too. 
To address this assumption and to investigate aminopepti- 
dase N-gene expression in lymphoid cells, we have created a 
competitive RT-PCR of APN mRNA.  Furthermore, neutral 
aminopeptidase activity of T cell lines was characterized in 
more detail to answer the question whether their aminopepti- 
dase activity could be attributed to APN. 
2. Materials and methods 
2.1. Cloning and partial deletion of an APN gene fragment 
The 1865-bp EcoRI fragment of the APN cDNA (kindly provided 
by A.T. Look) was cloned into the plasmid pSPTI9 (Boehringer 
Mannheim). The deletion of the APN cDNA fragment was achieved 
by BAL31 nuclease (USB) using the unique DraIII restriction site of 
the APN cDNA. Extent and position of the deletion were determined 
by sequencing using the 'cycle sequencing kit' (USB) and the DIG- 
labelled APN-specific primer A1. The sample was loaded on a 8% 
sequencing gel and electrophoretically separated by the direct blotting 
system GATC (MWG Biotec) as recommended by the manufacturer. 
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1. Introduction 
2.2. In vitro transcription 
1 #g pSPTI9/2 14 plasmid DNA was cut with BglI yielding three 
fragments. The 775-bp 'APN-like transcript' (Fig. 1) was synthesized 
by T7 polymerase using the 'Mega-script kit' (Ambion) following the 
manufacturer's instructions. Amount and integrity of the synthesized 
RNA were checked by denaturing agarose-gel ectrophoresis. Dilu- 
tions of the standard RNA fragment were stored at -80°C. 
Aminopeptidase N (CD13, EC 3.4.11.2) is a metallopepti- 
dase commonly expressed on the surface of various cell types. 
As far as cells of the hematopoetic system are concerned, amin- 
opeptidase N was generally believed to be exclusively expressed 
on cells of the myelo-monocytic lineages. Aminopeptidase N 
has been well-characterized with respect o its cellular localiza- 
tion as well as its biochemical and structural features [14]. The 
enzyme is involved in the final hydrolysis of nutrients and 
degradation of bioactive molecules such as neuropeptides, 
angiotensin, tuftsin and cytokines [1,5-7]. Recent data indicate 
that aminopeptidase N serves as a receptor for different ligands 
[8-11] and that it is possibly involved in processes of antigen 
presentation [12]. 
Human lymphocytes and related cell lines are predominantly 
CD 13-negative. There are several reports, however, describing 
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2.3. Competitive PCR 
2.3.1. Reverse transcription. RNA was extracted using the method 
of Chomczynski and Sacchi [20]. 50-300 ng total RNA from cells was 
mixed with an aliquot of a given dilution of the standard APN fragment 
on ice. Mixtures were transcribed into cDNA by 50 U moloney murine 
leukaemia virus reverse transcriptase asrecommended bythe manufac- 
turer (USB) using 1 ng APN-specific primer ART. 
2.3.2. Enzymatic" amplification of the cDNA. 1 #1 of the cDNA 
reaction mixture was used directly for enzymatic amplifications that 
were performed in 30 #1 reaction volume containing 1 U Taq polym- 
erase (Amersham), 5 mM dNTP, 0.2 pmol of primers A1 and A2 and 
Ix reaction buffer (Amersham) in an Autogene II (Grant). Initial de- 
naturation at 94°C for 3 min was followed by 30 cycles with denatura- 
tion at 95°C for 0.7 min, annealing at 54°C for 0.6 min and elongation 
at 72°C for 1.3 rain. The final extension step was at 72°C for 10 min. 
5/11 of each reaction mixture was applied on an 1.8% agarose gel and 
stained with ethidium bromide. A photograph of the illuminated gel 
(Polaroid 667) was scanned using the densitometer CD60 (Desaga) at 
410 nm. 
2.3.3. Calculation f ,4PN mRNA amounts. Peak areas of the den- 
sitograms correspond to fluorescence intensity of DNA bands. The 
ratio of the peak areas of the wildtype and standard fragments was 
calculated to determine APN mRNA amount. The APN mRNA copy 
numbers/#g total RNA have been calculated taking into account he 
molecular weight (Mr = 249077) ofthe 'APN-like transcript'. Absolute 
copy numbers of APN transcript/cell are based on the ascertained RNA 
contents of the cells. 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)01139-0 
342 
2.4. Enzymatic assay 
Total neutral aminopeptidase activity was measured by determina- 
tion of the Ala-p-NA-hydrolysing activity of vital cells and correspond- 
ing cellular fractions, respectively. All measurements were made in 
triplicate as previously described [13]. The presence of APN was de- 
tected using APN-specific effectors, such as the anti-CD 13 monoclonal 
antibody WMI5 [21] and the APN-specific inhibitor probestin [22]. 
Briefly, cells were disintegrated bya 30-min incubation on ice in PBS 
1% Triton X100, pH 7.4. Particulate material was removed by centrif- 
ugation at 4°C, 100.000 x g for 30 min. Intact vital cells and the corre- 
sponding lysates, respectively, were pr incubated in the presence of the 
effectors (WM15; probestin, 10 -6 M) at room temperature for 30 min. 
Afterwards, Ala-p-NA-hydrolysing activity was measured in the pres- 
ence of the effectors [13]. 
3. Results 
3.1. Competitive RT-PCR 
The clone lacking 87 bp of the APN cDNA fragment, named 
pSPT19/2-14, was chosen as the standard fragment for the 
competitive PCR (Fig. 1). 40 copies of the 'APN-like transcript' 
were detectable by RT-PCR (not shown). The same copy num- 
ber has been determined after storage of the standard RNA at 
-80°C for 3 months. This implied that the standard RNA 
template is stable under these conditions (not shown). Titration 
experiments using wildtype and standard DNA fragments 
clearly showed linearity of the competitive system in a broad 
concentration range (Fig. 2). The linearity of the ratio wildtype/ 
standard fragment is guaranteed over 6 consecutive dilution 
steps (dilution factor 2) if the ratio of both fragments amounts 
among 0.4 and 16. The ratio of the wildtype/standard fragment 
of a given sample was identical after 25, 30 and 35 cycles, 
respectively (not shown). 
3.2. Quantification of  APN mRNA content of  cell lines 
Quantification of the APN mRNA content in cell lines was 
performed in two steps as described above. The cell line U937 
A EcoKI Bgll EcoRI 
B 
+1 
+61 
+121 
+181 
+241 
+301 
+381 
clone pSPT 19/2-14 • Ioealisation f the deletion 
ATGgccaagg gcttctatat ttccaagtcc ctgggcatcc tggggatcct gggcgtggca 
gccgtgtgca caatcatcgc actgtcagtg gtgtactccc aggagaagaa caagaacgcc 
aacagctccc ccgtggcctc caccaccccg tccgcctcag ccaccacaaa c¢ccgcctcg 
gccaccacct tggaccaaag taaagcgtgg aatcgttacc gcctccccaa cacgctgaaa 
cccga£tcct accaggtgac gctgagaccg tacctcaccc ccaatgacag gggcctgtac 
gtttt~aagg gctccagcac cgtccgtttc acctgcaagg 8ggccACTGA ~T~2&TC 
&~tGC.A  J~&AGCTC~ ~.F&~,CCC~O 8~CCAGGGGC AC~G~O"Z 
+421 ~J~gGG~SGCT CCcagccccc cgacattgac aagactga~c tggtggagcc caccgagtac 
( A 2 - -  
+481 ctggtggegc acctcaaggg ctccctggtg aaggacagcc agtatgagat ggaeagegag 
( ART - -  
+541 ttcgaggggg agttggcaga tgacctggcg ggcttctacc gcagcgagta catggagggc 
+601 aatgtcagaa aggtggtggc cactacacag atgcaggctg cagatgcccg gaagtccttc 
+661 ccatgcttcg atgagccggc 
Fig. 1. Partial map and sequence of the APN cDNA fragment, cloned 
in the plasmid pSPT19/2 14. Part A gives locations of the deletion i
the clone pSPTI 9/2-14 and of BglI site, used for restriction of plasmid 
DNA prior the in vitro transcription. B shows a part of the APN 
cDNA, sequence lacking in the clone pSPT19/2-14 (capital and bold 
letters) and the primer binding sites of primers A 1, A2 and ART, those 
were used in RT-PCR. The sequence starts with the first codon (ATG) 
and is presented as far as the BglI restriction site. The 775-bp "APN-like 
transcript' consists of a 64-bp vector fragment, the 118-bp region that 
is located ownstream ofthe start codon and the given cDNA sequence 
(593 bp). Complete APN cDNA sequence was published by A.T. Look 
and co-workers [4]. 
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Fig. 2. Usage of the APN standard fragment in the competitive PCR. 
(A) PCR on dilutions of DNA mixes, consisting of wildtype (wt) and 
standard DNA (sf). 0.3 ng wildtype plasmid-DNA (pSPT19/2) was 
mixed with decreasing amounts of standard plasmid-DNA (pSPT 19/2- 
14; lane 1-9:10 ng-39 pg; dilution factor 2) and amplified as described. 
The sizes of both fragments are 468 bp for APN cDNA fragment and 
381 bp for the standard fragment, respectively. M, molecular weight 
marker VIII (Boehringer Mannheim) (B) Plot of determined ratios 
from consecutive dilutions of wildtype and standard fragment. Ratios 
were obtained by scanning photograph given in Fig. 2A. Dilution fac- 
tors (1 256) correspond to lanes 1 9, illustrated in Fig. 2A. The 
equimolar concentration f both fragments was calculated at dilution 
factor 28. The determined ratios were fitted among dilution factors 2 
and 128. These results were confirmed by three additional experiments 
(not shown). 
(Fig. 3) as well as the two T cell lines H9 and HUT78 (not 
shown) contain APN mRNA. 2.3 × 107, 5.9 × 106 and 5.6 × 106 
copies//tg total RNA, respectively, were calculated for the 
myelo-monocytic cell line U937 and the lymphoid T cell lines 
HUT78 and H9. Taking into account he RNA content, U937 
holds ~ 160 copies of APN mRNA/cell whereas the T cell lines 
H9 and HUT78 contain 50 and 70 copies, respectively (Table 
1). 
3.3. Detection of  APN-derived enzymatic activity 
In contrast to the myelo-monocytic cell line U937, T cell lines 
H9 and HUT78 are CD13-negative using immunfluorescense 
analysis (not shown). In spite of this fact, both T cell lines 
express considerable neutral aminopeptidase activities, meas- 
ured by the cleavage of the chromogenic substrate Ala-p-NA 
(Table 1). However, only the aminopeptidase activity of U937 
cells could be significantly inhibited by the anti-CD 13 monoclo- 
nal antibody WM15. In contrast, aminopeptidase activities of 
both T cell lines were not affected (Table 1). Furthermore, the 
inhibitor probestin (10 -6 M) strongly affects aminopeptidase 
activity of vital U937 cells (18% residual activity) but the corre- 
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Fig. 3. Determination f the APN mRNA content of the myelomon- 
ocytic ell line U937. (A) 500 ng total RNA from U937 was mixed with 
the APN standard fragment (4 × 108 102 copies), reverse-transcribed 
and amplified using primers AI and A2 (lanes 1-7). (B) 500 ng total 
RNA from U937 was mixed with the APN standard fragment 
(2.6 x 108-2 × 10 6 copies), reverse-transcribed and amplified as de- 
scribed above (lanes 1-8). M, molecular weight marker V (Boehringer 
Mannheim). 
sponding activities of H9 and HUT78 cells were decreased to 
58 and 78%, respectively, only (not shown). 
4. Discussion 
Experiments reported in this paper are aimed at the detection 
of APN transcript using the competititive RT-PCR technique. 
APN-specific mRNA is detectable and could be quantified in 
the lymphoid cell lines HUT78, H9 and in the CD 13-positive cell 
line U937, respectively. The usage of intron-overspanning 
primers in the experiments proved that amplified DNA frag- 
ments indeed originate from APN mRNA, instead of from 
contaminating by DNA. Data obtained from competition of 
the APN standard by the APN wildtype fragment clearly dem- 
onstrate that this RT-PCR system works well over a broad 
range. The experimental determined ratios of the fluorescence 
intensities of the DNA fragments (wildtype and standard) accu- 
rately correspond to the given dilution factor (Fig. 2A,B). 
Therefore, it could be concluded that absolute values of these 
ratios among 0.4 and 16 are suitable for exact quantification 
of APN mRNA transcript level, and it is not necessary to titre 
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the amount of standard RNA to equal amounts of the APN 
mRNA to ensure a ratio of nearly 1. 
Data presented here provide evidence that the APN gene is 
really expressed inT cells. Furthermore, the results are in agree- 
ment with qualitative RT-PCR analysis on peripheral T cells 
and T cell lines [13,17]. The detection of APN transcripts in T 
cells contradicts to previous tudies reporting that the APN 
expression is restricted to the myelo-monocytic cells and their 
progenitors [14,19]. The attempts of others to detect APN 
mRNA in lymphoid cells by Northern blotting failed until yet, 
suggesting a low copy number of APN gene transcript in these 
cells [19]. The detected copy numbers in a range of 50-160 
copies/cells confirm this assumption. The values are in the 
range of class II mRNAs, occurring at 20-3500 copies/cell. The 
discrepancy between the Northern analysis and the RT-PCR 
may be xplained by the higher sensitivity of the PCR method. 
The CD 13-positive U937 contains 2-3 times more APN tran- 
script/cell than both T cell lines found to be CDl3-negative. 
The APN copy numbers of the cells, determined by the RT- 
PCR, have been confirmed by analysis of the APN-derived 
enzymatic activity. Although H9 and HUT78 cells express neu- 
tral aminopeptidase activities equal to or higher than U937, 
respectively, only a minor fraction of the aminopeptidase activ- 
ity in T cells really originates from the APN gene. This could 
be concluded from the lack of inhibition of the enzymatic activ- 
ity by the antibody WM15, strongly decreasing APN activity 
[21] and the low inhibition of enzymatic activity by the APN- 
specific inhibitor probestin [22]. Summarizing these data, it 
could be concluded that only 5 20% of total neutral aminopep- 
tidase activities in T cells represent membrane-bound APN. In 
contrast, 60 70% of the neutral aminopeptidase activity are 
derived from the APN gene in U937 cells. Furthermore, the 
aminopeptidases from U937 cells and T cells (H9 and HUT78) 
differ in their molecular weights, isoelectric points, inhibition 
rates by inhibitors and cellular localizations (unpubl. data). 
APN mRNA copy numbers determined in our experiments 
are specific with respect o the proliferative status of the cells. 
Changes of the RNA content, normally occurring during differ- 
ent growth phases of cells, strongly affect cellular copy numbers 
of transcripts. To circumvent these variations, cells were har- 
vested in each experiment at the beginning of the stationary 
phase after 72 h. 
Results reported in the present study show that APN gene 
expression is not restricted to myelo-monocytic cells, clearly T 
cells and derived cell lines are able to express aminopeptidase 
N although on a low level. The main aminopeptidase expressed 
in T cells seems to be a previously unknown enzyme, which is 
Table 1 
APN mRNA contents and Ala-p-NA-hydrolysing activity of myelo-monocytic cell line U937 and T cell-derived cell lines H9 andHUT78 
Cell line APN mRNA Total RNA APN mRNA AIa-p-NA hydrolysis Inhibition of AIa-p-NA 
copies//zg /2g/106 cells copies/cell (pkat/106 cells) hydrolysis by WM15 
total RNA (residual activity, 
% of control) 
U937 2.3 × 10 7 7 160 84.8 + 3.2 58.4 + 13.5 
HUT78 5.9 × 10 6 9 50 108.2 + 22.2 99.8 + 0.5 
H9 5.6 × 10 6 12 70 66.1 + 14.8 98 + 3.2 
All values are at least means oftwo experiments and correspond tocells harvested in theearly-stationary phase. Enzymatic activity and its inhibition 
by the anti-CDl 3 monoclonal ntibody was measured in the lysate of cells. 
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not related to APN, and which has to be characterized in more 
detail. 
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